Radiotherapy & Oncology

AIMS AND SCOPE

Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes clinical radiotherapy, combined modality treatment, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as physical aspects relevant to oncology, particularly in the field of imaging, dosimetry and radiation therapy planning. Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.

EDITOR-IN-CHIEF
Michael Baumann, Heidelberg, Germany

EDITOR-IN-CHIEF EMERITUS
Jens Overgaard, Aarhus, Denmark

PHYSICS EDITOR EMERITUS
David Thwaites, Sydney, Australia and Leeds, UK

EDITORS

M. Alber, Aarhus, Denmark
M. A. Appelt, Leeds, UK
P. Blanchard, Villejuif, France
M. Bolla, Genoble, France
J. M. Borras, Barcelona, Spain
T. Bortfeld, Boston, US
J. Bouhis, Lausanne, Switzerland
M. Brada, Bebington, UK
J. Bussink, Nijmegen, The Netherlands
R. Butel, Dresden, Germany
F. A. Calvo, Madrid, Spain
A. Chalmers, Glasgow, UK
J. M. Crook, Kelowna, Canada
O. Dahl, Bergen, Norway
G. de Meerleer, Leuven, Belgium
D. De Ruyscher, Maastricht, The Netherlands
A. Eisbruch, Ann Arbor, US
S. Faithful, Guildford, UK
C. Fiorino, Milan, Italy
E. Fokas, Frankfurt, Germany
D. van der Heide, Amsterdam, Netherlands
M. Alber, Aarhus, Denmark
M. A. Appelt, Leeds, UK
P. Blanchard, Villejuif, France
M. Bolla, Genoble, France
J. M. Borras, Barcelona, Spain
T. Bortfeld, Boston, US
J. Bouhis, Lausanne, Switzerland
M. Brada, Bebington, UK
J. Bussink, Nijmegen, The Netherlands
R. Butel, Dresden, Germany
F. A. Calvo, Madrid, Spain
A. Chalmers, Glasgow, UK
J. M. Crook, Kelowna, Canada
O. Dahl, Bergen, Norway
G. de Meerleer, Leuven, Belgium
D. De Ruyscher, Maastricht, The Netherlands
A. Eisbruch, Ann Arbor, US
S. Faithful, Guildford, UK
C. Fiorino, Milan, Italy
E. Fokas, Frankfurt, Germany

D. R. Gomez, Houston, US
A. Gomez-Turria, Barakaldo, Spain
C. Grau, Aarhus, Denmark
V. Gregoire, Lyon, France
A. L. Grosu, Freiburg, Germany
M. Guckenberger, Zurich, Switzerland
X. Hao, Tianjin, China
S. B. Harrabi, Heidelberg, Germany
B. Heijmen, Rotterdam, The Netherlands
C. W. Hurkmans, Eindhoven, The Netherlands
G. O. Janssens, Utrecht, The Netherlands
J. Jin, Beijing, China
N. Jornet, Barcelona, Spain
J. H. A. M. Kaanders, Nijmegen, The Netherlands
O. Kaidar-Person, Ramat Gan, Israel
J. Kazmerska, Poznan, Poland
L. Kępka, Warsaw, Poland
T. Knöös, Lund, Sweden
T. Kron, Melbourne, Australia
P. Lambin, Maastricht, The Netherlands
J. A. Langendijk, Groningen, The Netherlands
M. Leech, Dublin, Ireland
Z. Liao, Houston, US
P. Maingon, Paris, France
B. Mijnheer, Amsterdam, The Netherlands
G. Minniti, Siena, Italy
G. C. Morton, Toronto, Canada
L. P. Muren, Aarhus, Denmark
M. Niyazi, Munich, Germany
B. Pieters, Amsterdam, The Netherlands
R. Pötter, Vienna, Austria
P. Poortmans, Wilrijk-Antwerp, Belgium
D. Rades, Lübeck, Germany
C. Salendri, Brussels, Belgium
F. A. Siebert, Kiel, Germany
M. Stock, Vienna, Austria
H. D. Suit, Boston, US
K. J. Tanderup, Aarhus, Denmark
D. Thorwarth, Tübingen, Germany
W. A. Tomé, New York, US
E. G. C. Troost, Dresden, Germany
T. Tramm, Aarhus, Denmark
Y. van der Linden, Leiden, The Netherlands
C. Vens, Amsterdam, The Netherlands
M. Verheij, Nijmegen, The Netherlands
D. Vordermark, Halle, Germany
M. C. Vozzen, Lausanne, Switzerland
H. Willers, Boston, US
B. Xu, Chongqing, China
Z. Zhang, Shanghai, China
D. Zips, Tübingen, Germany

Publication information: Radiotherapy & Oncology (ISSN 0167-8140). For 2022, volumes 166–177 (12 issues) are scheduled for publication. Subscription prices are available upon request from the Publisher or from the Elsevier Customer Service Department nearest you or from this journal’s website (http://www.thegreenjournal.com). Further information is available on this journal and other Elsevier products through Elsevier’s website (http://www.elsevier.com). Subscriptions are accepted on a prepaid basis only and are entered on a calendar year basis. Issues are sent by standard mail (surface within Europe, air delivery outside Europe). Priority rates are available upon request. Claims for missing issues should be made within six months of date of dispatch.

Radiotherapy & Oncology (ISSN 0167-8140) (USPS 13642) is published monthly by Elsevier B.V. (Radarweg 29, 1043 NX Amsterdam, the Netherlands). Airfreight and mailing in the USA by agent named World Container Inc, 150–15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Radiotherapy & Oncology, Air Business Ltd, c/o World Container Inc, 150–15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at Elsevier B.V. Radarweg 29, 1043 NX Amsterdam, the Netherlands. Air Business Ltd is acting as our mailing agent.

Advertising information. Advertising orders and inquiries can be sent to: USA, Canada and South America: Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169-0901, USA; phone: +(1) (212) 598 5800; Europe and ROW: Advertising Sales, Elsevier Pharma Solutions, 32 Jamestown Road, London NW1 7BY, UK; phone: +(44) (0) 20 7424 4259; fax: +(44) (0) 20 7424 4433; e-mail: elsevierpharma.uk@elsevier.com